Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- All Clinical Studies Need to Be Conducted According to Global Standards: Expert Committee
June 27, 2011
- Lenvatinib Shows ORR of 59% in Global PII: Eisai
June 27, 2011
- Merck to License Biosimilar of Enbrel from Hanwha of South Korea
June 27, 2011
- Daiichi Sankyo Confident about Independently Expanding Share for Memary
June 27, 2011
- Korosho to Enhance Generics' Reliability: Minister Hosokawa
June 27, 2011
- PIII Study Confirms Safety, Efficacy of Rotigotine Patch: Otsuka
June 27, 2011
- Mr Yoshida Points Out Need to Review NHI Pricing Rules for Generics
June 27, 2011
- New Prescription of Actos Suspended in France, Germany due to Bladder Cancer Risk
June 20, 2011
- Development of Anti-obesity Drug Contrave Suspended in US
June 20, 2011
- Chuikyo to Resume Discussions on Next Round of Drug Pricing Reform on June 22
June 20, 2011
- Agensys, Seattle Genetics to Codevelop ADC ASG-22ME: Astellas
June 20, 2011
- PMDA Accelerating Preparations for Membership in PIC/S
June 20, 2011
- DSP, TRANS GENIC, Univ. of Tokyo Sign Joint Research Agreement for AIM
June 20, 2011
- Concern Growing About Gov't Plan to Revise Patients' Drug Copayments
June 20, 2011
- Fujitsu, Univ. of Tokyo to Jointly Develop Technology for Creating LMW Compounds
June 20, 2011
- Fuso Applies for Surgical Hemostatic Product
June 20, 2011
- OncoTherapy Closes Patient Enrollment for PII Trial of OTS102 for Biliary Tract Cancer
June 20, 2011
- CellSeed Applies for Epithelial Cell Sheet for Corneal Regeneration
June 20, 2011
- FDA Not to Require PIII Data on Intranasal Granisetron: SNBL
June 20, 2011
- Daiichi Sankyo: Novel AD Treatment Memary Tablets
June 20, 2011
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…